Dicerna Pharmaceuticals (DRNA) Downgraded by Zacks Investment Research to “Sell”

Dicerna Pharmaceuticals (NASDAQ:DRNA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday, Zacks.com reports.

According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

A number of other equities analysts have also weighed in on DRNA. BidaskClub lowered Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Dicerna Pharmaceuticals in a research note on Friday, May 3rd. SunTrust Banks lifted their price target on Dicerna Pharmaceuticals to $26.00 and gave the company a “buy” rating in a research note on Wednesday, March 13th. ValuEngine lowered Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, April 26th. Finally, B. Riley lifted their price target on Dicerna Pharmaceuticals from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, March 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $22.13.

Shares of NASDAQ DRNA traded up $0.16 during mid-day trading on Wednesday, reaching $11.40. The company’s stock had a trading volume of 296,500 shares, compared to its average volume of 497,445. The firm has a market cap of $754.25 million, a price-to-earnings ratio of -9.50 and a beta of 2.30. Dicerna Pharmaceuticals has a 52 week low of $9.31 and a 52 week high of $17.98.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.16). The business had revenue of $3.11 million during the quarter, compared to the consensus estimate of $10.59 million. Dicerna Pharmaceuticals had a negative return on equity of 55.80% and a negative net margin of 1,284.93%. On average, sell-side analysts forecast that Dicerna Pharmaceuticals will post -0.99 earnings per share for the current fiscal year.

In other Dicerna Pharmaceuticals news, insider James B. Weissman sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $15.00, for a total transaction of $225,000.00. Following the completion of the sale, the insider now directly owns 39,480 shares in the company, valued at approximately $592,200. The transaction was disclosed in a document filed with the SEC, which is available through this link. 19.85% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. grew its stake in Dicerna Pharmaceuticals by 46.0% in the 4th quarter. BlackRock Inc. now owns 4,331,228 shares of the biopharmaceutical company’s stock worth $46,300,000 after acquiring an additional 1,364,155 shares during the period. Vanguard Group Inc lifted its stake in Dicerna Pharmaceuticals by 40.7% during the third quarter. Vanguard Group Inc now owns 1,983,272 shares of the biopharmaceutical company’s stock valued at $30,265,000 after purchasing an additional 573,197 shares during the last quarter. Vanguard Group Inc. lifted its stake in Dicerna Pharmaceuticals by 40.7% during the third quarter. Vanguard Group Inc. now owns 1,983,272 shares of the biopharmaceutical company’s stock valued at $30,265,000 after purchasing an additional 573,197 shares during the last quarter. RTW Investments LP lifted its stake in Dicerna Pharmaceuticals by 8.2% during the fourth quarter. RTW Investments LP now owns 5,907,088 shares of the biopharmaceutical company’s stock valued at $63,147,000 after purchasing an additional 445,964 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Dicerna Pharmaceuticals by 3,144.4% during the first quarter. JPMorgan Chase & Co. now owns 445,722 shares of the biopharmaceutical company’s stock valued at $6,530,000 after purchasing an additional 431,984 shares during the last quarter. Institutional investors own 86.16% of the company’s stock.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

See Also: What is the Quick Ratio?

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.